We are thrilled to announce that the highly anticipated N-Nitroso impurities of Amide and Indole have now been successfully developed e.g. N-Nitroso Orlistat , N-Nitroso Ropinirole , N-Nitroso Caprolactam ,N-Nitroso Gabapentin EP Impurity A , N-Nitroso Rizatriptan , N-Nitroso Zolmitriptan, N-Nitroso Naratriptan , N-Nitroso Tadalafil , N-Nitroso Eletriptan etc. are ready Stock
search icon
We are thrilled to announce that the highly anticipated N-Nitroso impurities of Amide and Indole have now been successfully developed e.g. N-Nitroso Orlistat , N-Nitroso Ropinirole , N-Nitroso Caprolactam ,N-Nitroso Gabapentin EP Impurity A , N-Nitroso Rizatriptan , N-Nitroso Zolmitriptan, N-Nitroso Naratriptan , N-Nitroso Tadalafil , N-Nitroso Eletriptan etc. are ready Stock

Menu

Nitroso

Nitrosamines are a group of chemical compounds that contain the nitroso functional group (NO) attached to an amine group (-NH). They can form in various ways, including through industrial processes, combustion, and certain chemical reactions, particularly involving nitrites and secondary amines. Nitrosamines are of concern because Many nitrosamines (N-Nitrosamines) are potent genotoxins; some have been classified as possible human carcinogens, although the degree of risk can vary depending on factors such as the amount of exposure and individual susceptibility. Synchemia Research Chemical is dedicated to thoroughly investigating the formation of nitroso impurities in APIs, including those related to the manufacturing processes. This approach indicates a proactive stance toward quality control and regulatory compliance. By exploring all potential sources of nitroso impurities, including those arising from the production processes themselves, Synchemia Research Chemical demonstrates a commitment to ensuring the purity, safety, and efficacy of their pharmaceutical products. Nitrosoamines, including N-Des-methyl Nitroso impurities, are important in pharmaceutical research and development due to their potential impact on drug safety and efficacy. Understanding and controlling the presence of these impurities is crucial for ensuring the quality and safety of pharmaceutical products. Can N-Nitrosamines exist in two different stable forms? N-nitrosamines substituted with two different alkyl groups can exist in two different stable forms distinguishable by several analytical methods. The two rotamers may differ in their overall dipole moment and therefore may posses different chemical and physical properties. Why do I see two peaks when analyzing N-Nitrosamines by HPLC or GC? HPLC and GC)analysis of N-nitrosamines may show two rotamers of the N-nitrosamine as two separate peaks. Whether two peaks are observed depends on the structure of the N-nitrosamine (i.e., symmetric vs. asymmetric) as well as the separation power of the analytical method.
We are the Synchemia Research Chemical specializes in manufacturing and exporting various nitrosoamine compounds, particularly focusing on N-Des-methyl Nitroso impurities of various APIs and nitroso compounds of direct APIs that contain secondary amines. By specializing in the synthesis and export of these compounds, Synchemia Research likely plays a significant role in supporting the pharmaceutical industry's efforts to meet regulatory requirements and ensure the highest standards of quality and safety in drug manufacturing.
download image Download catalogue

Pharmaceutical Reference Standards

Dabigatran Nitroso Impurity 7
Dabigatran Nitroso Impurity 7
CAT No SRC-N0141938
CAS No NA
Mol.F. C27H25N7O4
Mol.Wt. 511.5 g/mol
INV STATUS CUSTOM SYNTHESIS
Dabigatran Nitroso Impurity 11
Dabigatran Nitroso Impurity 11
CAT No SRC-N0141939
CAS No NA
Mol.F. C19H20N6O3
Mol.Wt. 380.4 g/mol
INV STATUS CUSTOM SYNTHESIS
Dabigatran Nitroso Impurity 12
Dabigatran Nitroso Impurity 12
CAT No SRC-N0141940
CAS No NA
Mol.F. C26H32N6O5
Mol.Wt. 508.6 g/mol
INV STATUS CUSTOM SYNTHESIS
Dabigatran Nitroso Impurity 19
Dabigatran Nitroso Impurity 19
CAT No SRC-N0141941
CAS No NA
Mol.F. C29H30N8O6
Mol.Wt. 586.6 g/mol
INV STATUS CUSTOM SYNTHESIS
Dabigatran Nitroso Impurity 20
Dabigatran Nitroso Impurity 20
CAT No SRC-N0141942
CAS No NA
Mol.F. C30H32N8O6
Mol.Wt. 600.6 g/mol
INV STATUS CUSTOM SYNTHESIS
Dabigatran Nitroso Impurity 21
Dabigatran Nitroso Impurity 21
CAT No SRC-N0141943
CAS No NA
Mol.F. C17H19N5O4
Mol.Wt. 357.4 g/mol
INV STATUS CUSTOM SYNTHESIS
Dabigatran Nitroso Impurity 22
Dabigatran Nitroso Impurity 22
CAT No SRC-N0141944
CAS No NA
Mol.F. C8H9N3O3
Mol.Wt. 195.2 g/mol
INV STATUS CUSTOM SYNTHESIS
Dabigatran Nitroso Impurity 23
Dabigatran Nitroso Impurity 23
CAT No SRC-N0141945
CAS No NA
Mol.F. C8H7N3O5
Mol.Wt. 225.2 g/mol
INV STATUS CUSTOM SYNTHESIS
Dabigatran Nitroso Impurity 24
Dabigatran Nitroso Impurity 24
CAT No SRC-N0141946
CAS No NA
Mol.F. C27H26N8O6
Mol.Wt. 558.6 g/mol
INV STATUS CUSTOM SYNTHESIS
Dabigatran Nitroso Impurity 8
Dabigatran Nitroso Impurity 8
CAT No SRC-N0141947
CAS No NA
Mol.F. C29H31N7O5
Mol.Wt. 557.6 g/mol
INV STATUS CUSTOM SYNTHESIS
Dabigatran Nitroso Impurity 25
Dabigatran Nitroso Impurity 25
CAT No SRC-N0141948
CAS No NA
Mol.F. C27H27N7O5
Mol.Wt. 529.6 g/mol
INV STATUS CUSTOM SYNTHESIS
Dabigatran Nitroso Impurity 26
Dabigatran Nitroso Impurity 26
CAT No SRC-N0141949
CAS No NA
Mol.F. C27H27N7O5
Mol.Wt. 529.6 g/mol
INV STATUS CUSTOM SYNTHESIS
N-Nitroso Dabigatran Etexilate EP Impurity B
N-Nitroso Dabigatran Etexilate EP Impurity B
CAT No SRC-N0141950
CAS No NA
Mol.F. C27H28N8O4
Mol.Wt. 528.6 g/mol
INV STATUS CUSTOM SYNTHESIS
Dolutegravir Nitroso Impurity 1
Dolutegravir Nitroso Impurity 1
CAT No SRC-N0141951
CAS No NA
Mol.F. C20H20F2N4O7
Mol.Wt. 466.4 g/mol
INV STATUS CUSTOM SYNTHESIS
Donepezil Nitroso Impurity 1
Donepezil Nitroso Impurity 1
CAT No SRC-N0141952
CAS No NA
Mol.F. C20H20F2N4O7
Mol.Wt. 466.4 g/mol
INV STATUS CUSTOM SYNTHESIS
Donepezil 2-Ethylbutyl Nitroso Impurity
Donepezil 2-Ethylbutyl Nitroso Impurity
CAT No SRC-N0141953
CAS No NA
Mol.F. C24H30N2O4
Mol.Wt. 410.5 g/mol
INV STATUS CUSTOM SYNTHESIS

Let’s advance your research together.

Partner with us for specialized chemical materials and synthesis services that enable pharmaceutical innovation.